Mach7 Technologies Posts 16% Revenue Rise, Cuts Loss by 22% in FY25
Mach7 Technologies Limited reported a 16% revenue increase to AUD 33.8 million for FY25, alongside a 22% reduction in net loss, driven by a strategic shift to subscription-based sales and disciplined cost management.
- 16% revenue growth to AUD 33.8 million
- Net loss narrowed by 22% to AUD 6.2 million
- Annual recurring revenue up 20%, now 72% of total revenue
- Operating expenses rose 9%, managed amid inflation and growth
- New CEO Teri Thomas appointed effective July 2025
Solid Revenue Growth and Loss Reduction
Mach7 Technologies Limited has released its audited financial results for the year ended 30 June 2025, reporting a 16% increase in revenue to AUD 33.8 million. This growth was accompanied by a 22% reduction in net loss, which narrowed to AUD 6.2 million from AUD 8.0 million the previous year. The company attributes this improvement to strong sales performance and disciplined cost control.
Shift Towards Subscription Model
A key highlight of the year was Mach7’s continued transition towards a subscription-based revenue model. Annual recurring revenue (ARR) grew by 20% to AUD 25.3 million, now representing 72% of total revenue. This shift reflects customer preference for operational expenditure models over upfront capital purchases, providing Mach7 with more predictable and stable revenue streams.
Operating Expenses and Cash Position
Operating expenses increased by 9% to AUD 31.8 million, driven by inflationary pressures and investments to support growth initiatives. Despite this, the company maintained disciplined expense management. Mach7 ended the year with a strong cash position of AUD 23.1 million and no debt, underpinning its financial stability.
Leadership Transition and Strategic Review
Effective 1 July 2025, Teri Thomas assumed the role of Chief Executive Officer, succeeding Michael Lampron who stepped down at the end of June. Ms. Thomas brings over 20 years of healthcare technology leadership, with a track record of driving growth and operational efficiency. Concurrently, Mach7 has paused its on-market share buy-back program, initiated in March 2025, pending the outcome of a comprehensive strategic review aimed at refining market positioning and growth strategy.
Global Operations and Market Focus
Mach7 operates globally with key markets in North America and Asia Pacific, delivering enterprise imaging software solutions to healthcare providers. The company’s product suite includes advanced diagnostic viewers, vendor-neutral archives, and workflow applications designed to enhance interoperability and clinical efficiency. Management remains focused on expanding subscription sales, particularly in North America, while leveraging its Asia-based teams to enhance customer support and R&D capacity.
Audit and Governance
The financial statements were audited by RSM Australia Partners, who issued an unmodified opinion. Key audit matters included revenue recognition, impairment assessment of goodwill and intangibles, and share-based payments. The company continues to maintain strong governance practices, with a board comprising experienced directors and a remuneration framework aligned with performance and shareholder interests.
Bottom Line?
Mach7’s FY25 results lay a foundation for growth, but investors will watch closely as the new CEO leads the strategic review and execution of the subscription-driven model.
Questions in the middle?
- What strategic directions will emerge from Mach7’s ongoing comprehensive review?
- How will the leadership transition impact execution and market expansion?
- Can Mach7 sustain its momentum in subscription sales amid competitive pressures?
